跳至主要内容
临床试验/NCT00331500
NCT00331500已完成3 期

A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Alcon Research0 个研究点目标入组 287 人开始时间: 2006年4月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
287
主要终点
Daily ocular itching and redness scores

研究概览

简要总结

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model

排除标准

  • Under 10 years of age

研究组 & 干预措施

Olopatadine Hydrochloride 0.2%

Experimental

Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks

干预措施: Olopatadine Hydrochloride Ophthalmic Solution, 0.2% (Drug)

Vehicle

Placebo Comparator

Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks

干预措施: Olopatadine Hydrochloride Ophthalmic Solution Vehicle (Drug)

结局指标

主要结局

Daily ocular itching and redness scores

时间窗: Up to Day 14

次要结局

  • Percentage of patients with daily ocular itching and redness scores of 0(Up to Day 14)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验